Prescription Costs

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Yea means supporting measures to lower prescription costs for Canadians through federal investment and policy coordination.

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).

Commitment to long-term funding to improve drug affordability, starting with rare disease drugs

Voting Nay means opposing the federal commitments or interventions aimed at reducing prescription costs, or disputing funding priorities (e.g., rare disease focus).